Prediction: This Stock Could Double Over the Next 5 Years
Weight loss drug developer Viking Therapeutics (NASDAQ: VKTX) has been in the news recently. The company offers substantial upside potential for investors, and although it is a speculative investment, it's attractive to risk-tolerant investors seeking a stock that could double in a few years. Here's why. The investment case hinges on its lead weight loss drug, VK2735. The GLP-1 and GIP agonist has shown rapid weight loss in clinical trials, and investors hope it will do so again in an ongoing phase 3 trial in subcutaneous (injectable) form. Even more exciting, Viking plans to initiate a phase 3 trial of VK2735 in oral formulation later in 2026. Image source: Getty Images. Continue reading